Dead On Target: Multifunctional Nanoparticle Platforms For Targeting And Imaging Cancer Cells
Xiangyang Shi, Suhe Wang, James R. Baker Jr., and their colleagues have designed dendrimer nanoparticle systems that are stable, water soluble, and biocompatible. The researchers start out by synthesizing gold nanoparticles within amine-terminated dendrimers. Next, dye molecules and a targeting molecule, folic acid, are attached to the ends of the dendrimers. Finally, the remaining amine groups are acetylated to ensure that the complex particles do not bear any surface charges. This last step is especially important to ensure the biocompatibility of these systems and to prevent the nonspecific adhesion of other materials. Molecular dynamics simulations indicate that the folic acid attachments project out into the solvent and are readily available for binding to cells, whereas the dye molecules stay far removed from the metal nanoparticles and thus retain their bright fluorescence.
Many cancer cells, including those implicated in cancers of the ovary, kidney, uterus, testis, brain, colon, and lungs, tend to overexpress folic acid receptors. Owing to the folic acid attachments grafted onto the dendrimer nanoparticles, the dendrimer nanoparticles are seen to latch onto the cancer cells via these folic acid receptors. Since the dendrimer nanoparticles are also equipped with dye molecules, the high concentrations of nanoparticles accumulated in the cancer cells can be imaged by confocal microscopy, and indeed diseased cells can be easily told apart from healthy cells. Further verification comes from electron microscopy experiments. The high contrast provided by the gold nanoparticles allows the determination of the specific sites in the cell machinery where the nanoparticles are attached. Shi pointed out that it should be possible to design dendrimer nanoparticles with other biological ligands such as proteins and antibodies to image and target various biological systems.
"Beyond imaging, it may also be possible to specifically target and destroy cancer cells that internalize the nanoparticles by applying laser heat that intensifies in the presence of gold nanoparticles", said Wang. "Another possibility is the attachment of drug molecules to these dendrimer nanoparticle systems", added Baker, "since this will allow the direct delivery of drugs to the target cells". The researchers are currently conducting further in vivo experiments to evaluate the suitability of this system for clinical applications.
Author: Xiangyang Shi, University of Michigan, Ann Arbor (USA)
Title: Dendrimer-Entrapped Gold Nanoparticles as a Platform
Small 2007, 3, No. 7, 1245-1252, doi: 10.1002/smll.200700054
About Small: Micro and Nano: No small Matter. Science at the nano- and microscale is currently receiving enormous wordwide interest. Published by Wiley-VCH, Small provides the very best forum for experimental and theoretical studies of fundamental and applied interdisciplinary research at these dimensions. Read an attractive mix of peer-reviewed Communications, Reviews, Concepts, Highlights, Essays, and Full Papers.
Contact: Xiangyang Shi
John Wiley & Sons, Inc.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:
Shi, Xiangyang. "Dead On Target: Multifunctional Nanoparticle Platforms For Targeting And Imaging Cancer Cells." Medical News Today. MediLexicon, Intl., 26 Jun. 2007. Web.
26 May. 2017. <http://www.medicalnewstoday.com/releases/75100.php>
Shi, X. (2007, June 26). "Dead On Target: Multifunctional Nanoparticle Platforms For Targeting And Imaging Cancer Cells." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.